Non Hodgkin Lymphoma Clinical Trial
A Study to Assess 7/8 HLA-matched Hematopoietic Stem Cell Transplantation Participants Treated With or Without Abatacept in Combination With a Calcineurin Inhibitor and Methotrexate
The purpose of this study is to estimate overall survival (OS) for participants treated with abatacept versus those not treated with abatacept prior to hematopoietic stem cell transplantation (HSCT). Participants were included if their donors were unrelated and had 1-allele mismatched human leukocyte antigen (HLA) status.
Participants who underwent first allogenic transplant in the US
Participants with an unrelated donor who are HLA-matched at 7/8 loci (A, B, C, DRB1)
Participants at least 6 years old with weight at least 20 kilograms
Participants with a Karnofsky/Lansky Performance Score ≥80%
Participants whose first allogeneic transplant occurred from January 1, 2011 to December 31, 2018
Participants with any of the following diseases: AML, ALL, CML, MDS, HL, NHL
Participants with any of the following graft versus host disease (GVHD) prophylaxis treatments:
CNI plus MTX (with or without ATG and with or without abatacept); or
Post-transplant cyclophosphamide (PT-Cy) without antithymocyte globulin (ATG)
Participants treated with any of the following conditioning regiments: total body irradiation (TBI)/cyclophosphamide (Cy), busulfan (Bu)/Cy, Bu/fludarabine (flu), Flu/Melphalan (MEL)
Participants with missing information on ATG (yes/no)
Participants receiving alemtuzumab (Campath)
Participants with cord blood grafts
Participants with non-MDS myeloproliferative disorders (NOTE: Participants with chronic myelomonocytic leukemia [CMMoL] will be included)
Participants who did not consent to participate in research
Participants treated at embargoed centers for research
Participants treated with abatacept and ATG
Among non-abatacept treated participants, participants transplanted at centers with abatacept trial participants
Participants with any of the following missing propensity score variables:
Disease status at transplantation (early, intermediate, advanced HL and NHL-chemosensitive)
Gender (male, female)
HSCT graft source (bone marrow [BM], peripheral blood [PB])
Conditioning intensity (myeloablative, non-myeloablative / reduced intensity)
Karnofsky/Lansky Performance Score (80%, 90-100%)
CNI type (tacrolimus, CsA)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Princeton New Jersey, 08540, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.